natgillin/translations-raw huggingface dataset:
The surface antigens in HBVaxPro are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
Površinske antigene v zdravilu HBVaxPro proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri kvasovka prejme gen (DNK), s katerim lahko tvori beljakovine.
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
Površinske antigene virusa hepatitisa B proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri kvasovka prejme gen (DNK), s katerim lahko tvori beljakovine.
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
Površinski antigeni virusa hepatitisa B se izdelujejo z metodo, ki se imenuje „tehnologija rekombinantne DNA“: proizvajajo jih kvasovke, ki so prejele gen (DNA), zaradi katerega lahko tvorijo te beljakovine.
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
Površinski antigeni virusa hepatitisa B se izdelujejo z metodo, ki se imenuje „tehnologija rekombinantne DNK“, pri kateri kvasovka prejme gen (DNK), s katerim lahko tvori beljakovine.
The surface dose rates and the accumulated dose depend on many factors.
Površinski odmerki in akumuliran odmerek so odvisni od mnogo dejavnikov.
The surgeon will organise the date for MACI implantation in consultation with the Marketing Authorisation Holder (MAH) or its local representative.
Kirurg bo določil dan za vsaditev zdravila MACI po dogovoru z imetnikom dovoljenja za promet z zdravilom ali njegovim lokalnim predstavnikom.
The surgical nature of the underlying procedure for the implantation of Holoclar has a major influence on the ability to drive and use machines.
Zaradi narave kirurškega posega, potrebnega za implantacijo zdravila Holoclar, ima zdravilo pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
The surgical procedure will have a major impact on your ability to drive and use machines.
Kirurški poseg bo bistveno vplival na vašo sposobnost vožnje ali upravljanja strojev.
The surgical procedure will have a major influence on your ability to drive and use machines.
Kirurški postopek bo imel velik vpliv na vašo sposobnost upravljanja vozil in strojev.
The surveillance programme/registry should prompt doctors to report adverse reactions
Program/register nadzorovanja mora spodbujati zdravnike, da poročajo o neželenih učinkih.
The surveillance programme/registry should prompt doctors to report adverse reactions.
Program/register nadzorovanja mora spodbujati zdravnike, da poročajo o neželenih učinkih.
The survival rate was 93.7% in the TAC arm and 91.4% in the FAC arm, at the 8-year follow-up timepoint, and 91.3% in the TAC arm and 89% in the FAC arm, at the 10-year follow-up timepoint.
Po 8 letih spremljanja je bil delež preživetja v kraku TAC 93,7 % in v kraku FAC 91,4 %, po 10 letih spremljanja pa je bil v kraku TAC 91,3 % in v kraku FAC 89 %.
The suspended product will be yellow and opaque. (See Figure C)
Suspendirano zdravilo bo rumeno in neprozorno. (Glejte Sliko C)
The suspension can be drawn up via a syringe or swallowed directly by the patient.
Suspenzijo se lahko izsesa z injekcijsko brizgo ali jo bolnik zaužije neposredno.
The suspension can be drawn up with a syringe or swallowed directly by the patient.
Suspenzijo lahko izsesate z injekcijsko brizgo ali pa jo zaužijete neposredno.
The suspension can be given using either of the two measuring syringes provided in the package (depending on weight of dog).
Suspenzijo je treba odmeriti z merilno brizgalko, ki je sestavni del pakiranja (odvisno od teže psa).
The suspension can be given using either of the two measuring syringes provided in the package.
Suspenzijo je treba odmeriti z merilno brizgalko, ki je sestavni del pakiranja.
The suspension can be given using the Inflacam measuring syringe provided in the package.
Suspenzijo lahko dajemo s priloženo merilno brizgo za Inflacam.
The suspension can be given using the measuring syringes provided in the package.
Suspenzijo lahko dajemo z merilno brizgo, ki je priložena pakiranju.
The suspension can be given using the Melosus measuring syringe provided in the package.
Suspenzijo lahko dajemo s priloženo merilno brizgo Melosus.
The suspension has a slightly acidic taste.
Suspenzija je kiselkastega okusa.
The suspension has to be given with the measuring syringe provided in the package of the 30 and 150 ml pack size or with one of the two measuring syringes provided in the package of the 10 ml pack size.
Suspenzijo je treba odmeriti z odmerno brizgalko, ki je sestavni del pakiranja po 30 ml ali 150 ml ali z eno od veh odmernih brizgalk, ki sta na voljo v pakiranju po 10 ml.
The suspension has to be given with the measuring syringes provided in the package of the 30 ml and 150 ml pack size or with one of the two measuring syringes provided in the package of the 10 ml pack size.
Suspenzijo je treba odmeriti z odmerno brizgalko, ki je sestavni del pakiranja po 30 ml ali 150 ml ali z eno od veh odmernih brizgalk, ki sta na voljo v pakiranju po 10 ml.
The suspension is a translucent to off white opalescent suspension, which may sediment slightly.
Suspenzija je prozorna do sivo bela opalescentna suspenzija, ki lahko rahlo sedimentira.
The suspension is a translucent to off white opalescent suspension, which may sediment slightly.
Suspenzija je prozorna do sivo bela opalescentna suspenzija, ki lahko rahlo sedimentira..
The suspension is administered in the patient’s mouth with an oral syringe without dilution.
Suspenzija se daje bolniku v usta z brizgo za peroralno dajanje brez redčenja.
The suspension is colourless to pale yellow, clear to opalescent.
Suspenzija je brezbarvna do bledorumena in bistra do rahlo motna.
The suspension is contained in type I flint glass cartridges, sealed with halobutyl disc seals and plunger heads and secured with aluminium seals.
Suspenzija je pakirana v steklene vložke iz kremenovega stekla tipa I, zaprte s tesnilno ploščico iz butilne ali halobutilne gume in z batnim zamaškom ter zaščitene z aluminijasto zaporko.
The suspension is given using the Loxicom measuring syringe provided in the package.
Suspenzijo je treba odmeriti z merilno brizgalko za Loxicom, ki je sestavni del pakiranja.
The suspension is opalescent and homogeneous.
Suspenzija je opalescentna in homogena.
The suspension is white to off-white.
Suspenzija je bela do sivkastobela.
The suspension is white to off-white.
Suspenzija je bele do sivo bele barve.
The suspension must be injected immediately after mixing the powder and the solvent.
Suspenzija mora biti injicirana nemudoma po mešanju praška in vehikla.
The suspension must be taken straight away.
Pripravljeno suspenzijo je treba popiti takoj.
The suspension must not be diluted.
Suspenzije ne smete redčiti.
The suspension needs to be shaken before use.
Suspenzijo je treba pred uporabo pretresti.
The suspension needs to be shaken well before use.
Suspenzijo je treba pred uporabo dobro pretresti.
The suspension of the marketing authorisation was lifted on 12 March 2014.
Začasni umik dovoljenja za promet z zdravilom je bil preklican 12. marca 2014.
The suspension powder is pale yellow with a citrus flavour.
Suspenzija je svetlorumena in ima okus po citrusu.
The suspension should be allowed up to 30 minutes prior to administration to reach room temperature (20 °C – 25 °C).
Pred uporabo pustite suspenzijo do 30 minut, da se segreje na sobno temperaturo (20 °C – 25 °C).
The suspension should be given using the Inflacam measuring syringe provided in the package.
Suspenzijo je treba dajati s priloženo merilno brizgo.
The suspension should be given using the Rheumocam measuring syringe provided in the package.
Suspenzijo je treba dajati s priloženo merilno brizgo.
The suspension should be mixed by gently rolling the vial prior to withdrawing each dose from the vial.
Suspenzijo je treba nežno premešati s kotaljenjem viale, preden iz viale izvlečete odmerek.
The suspension should be mixed by gently rolling the vial prior to withdrawing each dose from the vial.
Zdravilo je treba nežno premešati s kotaljenjem viale, preden iz viale izvlečete odmerek.
The suspension should be visually inspected prior to administration.
Pred uporabo je treba vizualno pregledati suspenzijo glede morebitnih tujih delcev.
The suspension, supplied in a bottle is whitish.
Suspenzija, ki je na voljo v steklenicah, je belkaste barve.
The sustained viral response achieved with 16 weeks of treatment and with 24 weeks of treatment was also examined in a retrospective subgroup analysis of patients who were HCV RNA negative by week 4 and had a LVL at baseline (see Table 16).
V retrospektivni analizi podskupine bolnikov, ki so bili HCV RNA negativni do 4. tedna in so imeli pred začetkom zdravljenja nizko virusno breme, so preučili tudi trajni virološki odziv, dosežen s 16- tedenskim in 24-tedenskim zdravljenjem (glejte preglednico 16).
The SVR rate was 62.5% (40/64) in subjects treated with Victrelis in combination with PR and 29.4% (10/34) in subjects treated with PR alone (see Table 6).
Delež SVR je znašal 62,5 % (40/64) pri preiskovancih, ki so bili zdravljeni z zdravilom Victrelis v kombinaciji s PR, in 29,4 % (10/34) pri preiskovancih, ki so bili zdravljeni samo s PR (glejte Preglednico 6).
The SVR rates for those who received at least one dose of Victrelis (i.e. excluding patients who discontinued during PR lead-in) are 41% for null responders, 67% for partial responders and 96% for relapsers.
Pri tistih, ki so prejeli vsaj en odmerek zdravila Victrelis (tj. brez bolnikov, ki so izstopili med uvajalnim obdobjem s PR), so bili deleži SVR 41 % pri popolnoma neodzivnih bolnikih, 67 % pri delno odzivnih bolnikih in 96 % pri bolnikih z recidivom.
The SVR rates in subjects randomized to receive ribavirin dose reduction and randomized to receive erythropoietin were comparable.
Delež SVR pri preiskovancih, randomiziranih v skupino, ki je prejemala zmanjšan odmerka ribavirina, in preiskovancih, randomiziranih v skupino, ki je prejemala eritropoetina, je bil primerljiv.
The SVR12 rate for the T12(b.i.d.)/PR group was 74% (274/369) compared to 73% (270/371) in the T12(q8h)/PR group with 95% confidence interval of the difference: -4.9%, 12.0%.
Stopnja SVR12 je bila za skupino T12(q8h)/PR 74% (274/369), v primerjavi s 73% (270/371) v skupini T12(q8h)/PR, pri čemer je 95% interval zaupanja za razliko -4,9%, 12,0%.
The swelling and damage due to these diseases cause the gradual loss of this central vision.
Otekanje in poškodbe, ki so posledica teh bolezni, povzročijo postopno izgubo središčnega vida.
The swelling generally resolves in 3 to 14 days but may persist in some cattle for up to 35 days after treatment.
Oteklina se običajno zmanjša v 3 do 14 dneh, pri določenem deležu goveda pa lahko izjemoma traja do 35 dni po uporabi zdravila.
The swelling should disappear within three weeks and should have no effect on the horse’s appetite, nor cause it any discomfort.
Oteklina običajno izgine v treh tednih in ne vpliva na apetit cepljenega konja, niti mu ne povzroča nelagodja.
The swellings typically resolve within 3 to 14 days but may persist in some animals for up to 35 days after treatment.
Oteklina se običajno zmanjša v 3 do 14 dneh, pri posameznih živalih lahko izjemoma vztraja do 35 dni po zdravljenju.
The swirling should only be stopped once the suspension appears uniform, white and all the powder on the bottom is dispersed.
Prenehajte z vrtenjem, ko opazite, da je suspenzija homogena in bela ter se je ves prašek na dnu razpustil.
The SWITCHMRK 1 & 2 (Protocols 032 & 033) studies evaluated HIV-infected patients receiving suppressive (screening HIV RNA < 50 copies/ml; stable regimen > 3 months) therapy with lopinavir 200 mg (+) ritonavir 50 mg 2 tablets twice daily plus at least 2 nucleoside reverse transcriptase inhibitors and randomized them 1:1 to continue lopinavir (+) ritonavir 2 tablets twice daily (n=174 and n=178, respectively) or replace lopinavir (+) ritonavir with raltegravir 400 mg twice daily (n=174 and n=176, respectively).
V študijah SWITCHMRK 1 in 2 (Protokola 032 & 033) so ovrednotili bolnike, okužene s HIV, ki so bili na supresivni terapiji (HIV RNA < 50 kopij/ml, stabilen režim > 3 mesece), in sicer 2 tableti z 200 mg lopinavirja (+) in 50 mg ritonavirja dvakrat na dan ter vsaj 2 nukleozidna zaviralca reverzne transkriptaze, in ki so jih randomizirali 1:1, tako da so nadaljevali z jemanjem po 2 tableti z lopinovirjem (+) ritonavirjem dvakrat na dan (n=174 oz. n=178) ali pa so lopinavir (+) ritonavir zamenjali z raltegravirjem v odmerku 400 mg dvakrat na dan (n=174 oz. n=176).
The symptoms (signs) of pandemic flu are similar to those of an ‘ordinary’ flu but are usually more severe.
Simptomi (znaki) pandemske gripe so podobni znakom ”navadne” gripe, vendar so običajno hujši.
The symptoms are usually of mild or moderate intensity (investigator’s assessment on a 4-point scale), and last for 1 to 4 days in most cases; in some cases, however, they may persist for 1 to 2 weeks or even longer.
Simptomi so običajno blagi ali zmerni (ocena raziskovalcev na štiristopenjski lestvici) in v večini primerov trajajo od enega do štirih dni; v nekaterih primerih lahko trajajo tudi en teden ali dva oziroma celo dlje.
The symptoms described above can be signs of the below listed side effects, which have been observed with Humira:
Opisani simptomi so lahko znaki naslednjih neželenih učinkov, ugotovljenih med uporabo zdravila Humira:
The symptoms described in connection with 280 mg esomeprazole were gastrointestinal symptoms and weakness.
Po zaužitju 280 mg so bili opisani simptomi na prebavilih in šibkost.
The symptoms described in these cases were consistent with the known adverse event profile of Tecfidera.
Simptomi, opisani v teh primerih, so skladni z znanim profilom neželenih učinkov zdravila Tecfidera.
The symptoms include sudden weight gain, swollen ankles and/or shortness of breath. if you have other severe diseases that are not well controlled.
Simptomi vključujejo nenadno povečanje telesne mase, otekanje gležnjev in/ali kratko sapo. če imate druge težke bolezni, ki niso dobro nadzorovane.
The symptoms include the following:
Simptomi so naslednji:
The symptoms include:
Simptomi so:
The symptoms include: akinesia (loss of muscle movement), rigid muscles, fever, unstable blood pressure, tachycardia (increased heart rate), confusion, depressed level of consciousness (e.g. coma).
Simptomi vključujejo: akinezijo (izguba mišične gibljivosti), trde mišice, povišano telesno temperaturo, nestabilen krvni tlak, tahikardijo (pospešeno bitje srca), zmedenost, zmanjšano stopnjo zavesti (npr. koma).
The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea.
Simptomi lahko vključujejo hladen znoj, utrujenost, glavobol, hitro utripanje srca, navale lakote, razdražljivost, živčnost ali slabost s siljenjem na bruhanje.
The symptoms may include one or more of the following: swelling, pain or rash around blood or lymph vessels, high level of a specific type of white blood cells (marked eosinophilia), worsening problems with breathing, nasal congestion, heart problems, pain, numbness, tingling in the arm and legs.
Simptomi lahko vključujejo enega ali več izmed naslednjih: oteklina, bolečina ali izpuščaj okrog krvnih ali limfnih žil, povečano število posebne vrste belih krvnih celic (izrazita eozinofilija), poslabševanje težav z dihanjem, kongestija nosne sluznice (zamašen nos), težave s srcem, bolečine, odrevenelost, mravljinčenje v rokah in nogah.
the symptoms of allergic rhinitis
simptomov alergijskega rinitisa.
The symptoms of fentanyl overdose are expected to be an extension of its pharmacological actions e.g. lethargy, coma and severe respiratory depression.
Pričakovani simptomi prevelikega odmerjanja fentanila so podaljšanje njegovega farmakološkega delovanja, npr. letargija, koma in resna depresija dihanja.
The symptoms of fentanyl overdose are expected to be similar in nature to those of intravenous fentanyl and other opioids, and are an extension of its pharmacological actions, with the most serious significant effects being altered mental status, loss of consciousness, hypotension, respiratory depression, respiratory distress, and respiratory failure, which have resulted in death.
Pričakovani simptomi prevelikega odmerjana fentanila so podobni simptomom intravensko apliciranega fentanila in drugih opioidiov, in so podaljšanje njegovega farmakološkega delovanja, med katerimi so bolj resni značilni učinki spremenjeno mentalno stanje, izguba zavesti, hipotenzija, respiratorna depresija, respiratorna stiska in respiratorna odpoved, ki se je končala s smrtjo.
The symptoms of fentanyl overdose are expected to be similar in nature to those of intravenous fentanyl and other opioids, and are an extension of its pharmacological actions, with the most serious significant effects being altered mental status, loss of consciousness, hypotension, respiratory depression, respiratory distress, and respiratory failure, which have resulted in death.
Pričakovani simptomi prevelikega odmerjana fentanila so podobni simptomom intravensko apliciranega fentanila in drugih opioidiv, in so podaljšanje njegovega farmakološkega delovanja, med katerimi so bolj resni značilni učinki spremenjeno mentalno stanje, izguba zavesti, hipotenzija, respiratorna depresija, respiratorna stiska in respiratorna odpoved, ki se je končala s smrtjo.
The symptoms of heart failure are caused by the heart not pumping enough blood around the body.
Do simptomov srčnega popuščanja pride takrat, ko srce ne more načrpati dovolj krvi po telesu.
The symptoms of JCV GCN are similar to PML.
Simptomi JCV GCN so podobni simptomom PML.
The symptoms of PML may be similar to an MS relapse (e.g. weakness or visual changes).
Simptomi PML so lahko podobni simptomom recidiva MS (npr. šibkost ali spremembe vida).
The symptoms of PML may be similar to an MS relapse.
Simptomi PML so lahko podobni recidivu MS.
The symptoms of serum sickness can be one or more of the following symptoms: joint pain with or without swelling or stiffness, rash, fever, swollen lymph nodes, muscle pain.
Simptomi serumske bolezni lahko vključujejo enega ali več izmed naslednjih simptomov: bolečine v sklepih z otekanjem ali okorelostjo ali brez njiju, izpuščaj, zvišana telesna temperatura, povečane bezgavke, bolečine v mišicah.
The symptoms of this condition include:
Med simptomi te motnje so:
The symptoms related to HSR worsen with continued therapy and can be life-threatening.
Simptomi, ki so pogojeni s preobčutljivostno reakcijo HSR, se z nadaljevanjem zdravljenja slabšajo in lahko postanejo življenjsko nevarni.
The symptoms related to this HSR worsen with continued therapy and can be life- threatening.
Simptomi, povezani s to preobčutljivostno reakcijo, se pri nadaljevanju terapije poslabšajo in so lahko življenjsko ogrožujoči.
The syndrome is generally delayed from several hours to several days after birth.
Sindrom se na splošno pojavi z zamikom več ur ali več dni po rojstvu.
The syndrome usually begins within several hours to 2 days following IVIg treatment.
Sindrom ponavadi nastopi v več urah do 2 dneh po zdravljenju z zdravili i.v.
The syndrome usually begins within several hours to 2 days following IVIg treatment.
Sindrom se ponavadi začne v več urah do 2 dneh po zdravljenju z i.v. imunoglobulini.
The syringe and needle should NEVER be reused.
Brizge in igle ne smete NIKOLI ponovno uporabiti.
The syringe and needles should NEVER be re-used.
Brizge in igle ne smete NIKOLI ponovno uporabiti.
The syringe and safety needle used to administer the injection are provided with the medicinal product.
Zdravilu sta priloženi injekcijska brizga in igla z varovalom, ki se uporabljata za injiciranje zdravila.
The syringe and the vial are for single use only.
Injekcijska brizga in viala sta le za enkratno uporabo.
The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 7 days (but not above 25°C).
Brizgo lahko vzamete iz hladilnika in jo pustite na sobni temperaturi enkrat za največ 7 dni (pri temperaturi do 25 °C).
the syringe cap is not detached from the Luer lock.
da pokrovček brizge ni odlomljen od nastavka Luer lock,
The syringe contains graduation marks corresponding to 135 micrograms (mcg), 90 mcg and 45 mcg.
Injekcijska brizga vsebuje oznake, ki ustrezajo 135 mikrogramom (mcg ali µg), 90 µg in 45 µg.
The syringe contains graduation marks corresponding to 180 micrograms (mcg), 135 mcg and 90 mcg.
Injekcijska brizga vsebuje oznake, ki ustrezajo 180 mikrogramom (mcg ali µg), 135 µg in 90 µg.
The syringe contains graduation marks corresponding to 90 micrograms (mcg), 65 mcg, 45 mcg, 30 mcg, 20 mcg and 10 mcg.
Injekcijska brizga vsebuje oznake, ki ustrezajo 90 mikrogramom (mcg ali µg), 65 µg, 45 µg, 30 µg, 20 µg in 10 µg.
The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20 °C-25 °C. If the elapsed time is longer than 30 minutes, the suspension should be discarded appropriately and a new dose prepared.
Brizgo, napolnjeno z rekonstituirano suspenzijo, lahko pustite do 30 minut pred uporabo, da doseže temperaturo približno 20 °C - 25 °C. Če poteče več kot 30 minut, morate suspenzijo ustrezno zavreči in pripraviti nov odmerek.
The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20 ºC-25 ºC. If the elapsed time is longer than 30 minutes, the suspension should be discarded appropriately and a new dose prepared.
Brizgo, napolnjeno z rekonstituirano suspenzijo, lahko pustite do 30 minut pred uporabo, da doseže temperaturo približno 20 °C – 25 °C. Če poteče več kot 30 minut, morate suspenzijo ustrezno zavreči in pripraviti nov odmerek.
The syringe fits onto the bottle and has a kg- body weight scale which corresponds to the maintenance dose.
Brizgalka je oblikovana tako, da se prilega plastenki in ima merilno skalo z oznakami telesne mase v kilogramih, ki ustrezajo vzdrževalnemu odmerku.
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the dose of 0.05 mg meloxicam/kg bodyweight.
Brizga je oblikovana tako, da se prilega kapalki na plastenki in ima merilno skalo z oznakami telesne mase v kilogramih, ki ustrezajo odmerku 0,05 mg meloksikama/kg telesne mase.
The syringe has a white tamper-evident cap.
Injekcijska brizga ima bel pokrovček, zaščiten pred odpiranjem.
The syringe has an integrated adapter and has a kg/bodyweight graduation.
Brizga ima na batu odmerni obroč in merilno skalo z oznakami telesne mase v kilogramih.
The syringe inside the pen is a 1 mL pre-filled syringe made of glass (Type I) with a bromobutyl rubber stopper and thermoplastic and polypropylene rigid needle shield, containing 0.5 mL of solution.
Brizga v napolnjenem injekcijskem peresniku je 1-ml napolnjena injekcijska brizga iz stekla (tip I) z zamaškom iz bromobutilne gume in termoplastičnim in polipropilenskim togim pokrovom za iglo, ki vsebuje 0,5 ml raztopine.
The syringe inside the pen is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic plunger.
Injekcijska brizga v peresniku je izdelana iz prozornega stekla tipa I z iglo velikost 27 iz nerjavečega jekla, gumijastim pokrovčkom igle in plastičnim batom.
The syringe is a disposable, pre-filled delivery device.
Napolnjena injekcijska brizga je napolnjen pripomoček za dostavo zdravila.
The syringe is equipped with a dark grey polypropylene plunger rod.
Brizga je opremljena s temno sivim nosilcem bata iz polipropilena.
The syringe is equipped with a light green polypropylene plunger rod.
Brizga je opremljena s svetlo zelenim nosilcem bata iz polipropilena.